Wednesday, December 14, 2011 9:16:43 PM
ViroPharma says FDA approved new label for Vancocin; says change could block generic versions
APAP – 4 hours ago
RELATED QUOTES
Symbol Price Change
VPHM 27.80 +4.21
EXTON, Pa. (AP) -- ViroPharma Inc. said Wednesday that regulators approved a new label for its antibiotic Vancocin with data on its safety and effectiveness, and the company believes the change will keep generic versions of the drug off the market for the next 3 years.
Shares of ViroPharma jumped $4.21, or 17.9 percent, to close Wednesday at $27.80. The stock was unchanged in aftermarket trading.
ViroPharma said the new label includes data on the safety and effectiveness of Vancocin as a treatment for Clostridium difficile, an intestinal infection that can cause symptoms ranging from diarrhea to potentially life-threatening inflammation of the colon. The drug is approved as a treatment for diarrhea associated with C. difficile and for gastrointestinal infections caused by Staphylococcus aureus.
The company said it believes the new labeling will prevent the approval for generic versions of Vancocin, or vancomycin, for another three years. In the third quarter, sales of the drug rose 13 percent to $76.6 million.
The information used in the new label comes from studies of Vancocin and an experimental drug being studied by Sanofi's Genzyme unit. ViroPharma said it bought the rights to use the studies. It will pay Genzyme royalties of 10 percent on net Vancocin sales over the next two years, and 16 percent the year after that.
FEATURED Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • May 15, 2024 10:30 AM
Swifty Global Announces Impressive Financial Results for Q1 2024 • DRCR • May 15, 2024 10:25 AM
Branded Legacy Inc. Invites Shareholders to Celebrate Milestones at Open House: Announces Share Buyback and Commitment to Authorized Share Count • BLEG • May 15, 2024 8:30 AM
Alliance Creative Group (ACGX) Releases Q1 2024 Financial and Disclosure Report with an 88% increase in Net Income from Q1 2023 to Q1 2024 • ACGX • May 15, 2024 8:30 AM
Category V Biotech, Inc. Announces Letter of Intent to Acquire Genetic Networks, Expanding into Biotechnology Sector • CATV • May 15, 2024 8:00 AM
POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • POET • May 14, 2024 10:09 AM